AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02452385
Drug: CM082 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM082 tablets taken orally
Trial: NCT02015949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily placebo tablet for two weeks
Trial: NCT01299467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
Trial: NCT00583674
Drug: AMG 386 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Trial: NCT00583674
Drug: AMG 386 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Trial: NCT00583674
Drug: AMG 386 3mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Trial: NCT00583674
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Trial: NCT00583674
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Trial: NCT03522415
Drug: Methotrexate（MTX）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate is a slow-acting antirheumatic drug.
Trial: NCT00935493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo po qhs
Trial: NCT01119066
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
Trial: NCT03936907
Drug: OWCP Orally Disintegrating Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
Trial: NCT03139032
Drug: APD334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD334 active treatment for 12 weeks.
Trial: NCT00742131
Drug: GSK1363089
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
Trial: NCT03794440
Drug: IBI305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg IV d1， Q3W
Trial: NCT00635141
Drug: hypertonic saline (7 %) and isotonic saline (0.9%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
Trial: NCT00635141
Drug: hypertonic saline (7 %) and isotonic saline (0.9%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
Trial: NCT01442337
Drug: ASP8597
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one time IV dose
Trial: NCT01442337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one time IV dose
Trial: NCT02804633
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram every 6 hours
Trial: NCT02804633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of normal saline every 6 hours
Trial: NCT00894699
Drug: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
Trial: NCT00894699
Drug: Placebo NanoTab™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of sublingual placebo NanoTab™
Trial: NCT00525668
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
Trial: NCT01905475
Drug: POL6326
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01905475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05567523
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT02243371
Drug: CY
RxNorm normalized name: CYT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
Trial: NCT02289365
Drug: 3000 mg of PEG-400 per day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
Trial: NCT02284256
Drug: Fibrocaps
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001335
Drug: ADR-529
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02941328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
Trial: NCT02263872
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 200mg perday
Trial: NCT01720303
Drug: isophane human insulin
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection s.c. (under the skin) at bedtime
Trial: NCT06285045
Drug: Roujin Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
Trial: NCT00838591
Drug: MN-221
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
Trial: NCT00838591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01699126
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin is an lipid lowering medication with anti-inflammatory effect.
Trial: NCT02931838
Drug: Placebo for BMS-986165
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01489865
Drug: ABT-888 and mFOLFOX-6
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
Trial: NCT04453826
Drug: Chemo-radiotherapy alone
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy
Trial: NCT01866748
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
Trial: NCT01866748
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
Trial: NCT04001439
Drug: Experimental drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
Trial: NCT00994825
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%
Trial: NCT04525144
Drug: Tebonin Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement: Gingko biloba EGb 761
Trial: NCT00912782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one time per week for 3 weeks
Trial: NCT05272397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
Trial: NCT01185938
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
Trial: NCT01771146
Drug: FOLFIRINOX Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
Trial: NCT01978145
Drug: FSC
RxNorm normalized name: Dofscort 3%-1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
Trial: NCT01978145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
Trial: NCT00003421
Drug: ABVD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003421
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003421
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01646515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks
Trial: NCT03657355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching-placebo will be used.
Trial: NCT04557657
Drug: Active bio Activa
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cement that release fluoride
Trial: NCT04557657
Drug: Resin Cement
RxNorm normalized name: Quick Cure resin cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin Cement Convinonal
Trial: NCT05546047
Drug: Acthar Gel 80 UNT/ML Injectable Solution
RxNorm normalized name: Acthar Gel 80 UNT/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
Trial: NCT01774786
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
Trial: NCT01774786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Trial: NCT01337219
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01898286
Drug: DiaPep277®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
Trial: NCT01778075
Drug: Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
Trial: NCT01778075
Drug: Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
Trial: NCT01597648
Drug: GSK2838510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
Trial: NCT03375086
Drug: APX3330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
Trial: NCT00682929
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
Trial: NCT00682929
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
Trial: NCT00682929
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
Trial: NCT00610792
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
Trial: NCT00456755
Drug: Shi-Bi-Lin
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of treatment, dose of 1 g (two capsules), twice daily
Trial: NCT06336395
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01048242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT06336395
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral/ intrathecal/intravenous/subcutaneous
Trial: NCT02479204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-33441-matching placebo
Trial: NCT01815424
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo BID for 16 weeks and then re-randomized into active groups
Trial: NCT01815424
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 5mg BID for 52 weeks
Trial: NCT01815424
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 10mg BID for 52 weeks
Trial: NCT01092182
Drug: EPOCH-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
Trial: NCT02081079
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Trial: NCT03942354
Drug: Directly observed therapy (DOT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy
Trial: NCT04645407
Drug: Fuzheng Huayu tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
Trial: NCT01282385
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
Trial: NCT01282385
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
Trial: NCT06336395
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT06336395
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01448889
Drug: 100% oxigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Trial: NCT01448889
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Trial: NCT06336395
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT00230776
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03886220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT02664909
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03214159
Drug: NORVIR tablet 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
Trial: NCT02068222
Drug: ABT-530
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01897727
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03533699
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets with no active drug
Trial: NCT01822080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily by mouth
Trial: NCT03724409
Drug: [90]Y-DOTATOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
Trial: NCT02441933
Drug: Taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses
Trial: NCT01061723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Trial: NCT00003730
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03837873
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/m2, continuous i.v. on day 1-4
Trial: NCT03837873
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/m2, i.v. on day5
Trial: NCT03245008
Drug: MT-5547-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in pre-filled syringe
Trial: NCT00654160
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00654160
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes